Light exposure therapy for myopia control: a systematic review and Bayesian network meta-analysis.
K. Kam,Alvin L. Young,Fang Yao Tang,Ebenezer Zaabaar,Patrick Ip,S. K. Szeto,Yuzhou Zhang,L. J. Chen,J. Yam,X. Zhang,C. Tham,C. Pang,Ian C. K. Wong,Christine H. T. Bui
DOI: https://doi.org/10.1136/bjo-2023-323798
2023-12-13
British Journal of Ophthalmology
Abstract:AIMS
To compare and rank the myopia control effects of different light wavelengths in children using a systematic review and Bayesian network meta-analysis (Bayesian NMA).
METHODS
The review protocol was registered with PROSPERO. We searched PubMed, EMBASE and MEDLINE for relevant clinical and animal studies published as of 2 February 2023. We included studies comparing red, violet or full-spectrum light with controls. Data extracted included descriptive statistics and study outcomes (axial length (AL) elongation and progression of spherical equivalent (SE) refraction). After quality assessment, estimates of treatment effect outcomes (mean differences (MDs) and 95% CIs) were first pooled for the animal and clinical studies in a traditional meta-analysis. To compare and rank the different light wavelengths, the Bayesian NMA was then conducted for all the included clinical studies (12 studies) and separately for only randomised controlled trials (8 studies). MDs, 95% credible intervals (CrIs) and ranks of the various light wavelengths were estimated in the Bayesian NMA.
RESULTS
When all clinical studies were included in the Bayesian NMA (12 studies), only red-light significantly slowed AL elongation, MD (95% CrI), -0.38 mm (-0.59 mm to -0.16 mm)/year and SE refraction progression, 0.72D (0.35D to 1.10D)/year compared with controls. It remained the only significant intervention when effect sizes from only RCTs (eight studies) were separately combined, (-0.28 mm (-0.40 mm to -0.15 mm)/year and 0.57D (0.22D to 0.92D)/year, for AL and SE refraction, respectively).
CONCLUSION
Myopia control efficacy varied among different wavelengths of light, with red light ranked as the most effective.
PROSPERO REGISTRATION NUMBER
Clinical studies: CRD42022368998; animal studies: CRD42022368671.
Medicine